Latest Patent Filing News

Biome Australia’s Activated Probiotics brand surpasses one million boxes sold in Australia, approaches top pharmacy ranking, and launches nationally in Canada, setting the stage for FY26 profitability.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Racura Oncology has detailed how its lead drug candidate, (E,E)-bisantrene, silences the cancer-driving MYC gene by stabilising G-quadruplex DNA structures, providing critical preclinical validation ahead of ongoing clinical trials.

Clover Corporation has reported a robust first half for FY26, with revenue climbing 17% and margins expanding significantly, underpinning a confident revenue forecast for the full year.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

IPH Limited reported a solid half-year performance with revenue up 6.5% to $363.9 million and net profit rising 10.5% to $41.2 million, driven by strong gains in Canada and Asia despite a decline in Australia and New Zealand.

Critical Resources Limited has launched a six-month evaluation program in partnership with the South Dakota School of Mines & Technology to develop next-generation solid-state lithium-ion battery materials, aiming to reduce technical risks and accelerate prototype development.

TG Metals has lodged a provisional patent application for a new technology that significantly improves lithium recovery and concentrate quality at its Burmeister deposit in Western Australia.

Zeotech Limited is set to validate its zeolite-based methane biofilter in a six-month on-site trial at a North Burnett landfill, aiming to curb emissions by over 90%. This marks a critical step from lab success to real-world application, supporting Australia’s climate goals.

INOVIQ Limited has reported compelling preclinical results for its CAR-NK-exosome therapy targeting triple-negative breast cancer, showing significant tumor reduction and perfect survival in treated mice.

Race Oncology has filed pivotal patents on the active (E,E)-bisantrene isomer, potentially extending its drug exclusivity by two decades, while advancing its Phase 1 clinical trial and maintaining a strong cash position.

First Graphene Limited has reported its strongest first quarter sales ever for its PureGRAPH products, alongside new product launches and strategic partnerships that position it at the forefront of advanced materials innovation.